• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

CO33 Methodological Challenges and Considerations for Decision Makers When Assessing within-Class Comparative Effectiveness and Cost-Effectiveness: The Case of Non-Vitamin K Antagonist Oral Anticoagulants
The United Kingdom National Institute of Health Care Excellence (NICE) published a draft clinical guideline for consultation on anticoagulation therapy for stroke prevention in individuals with atrial fibrillation in September 2020 that addressed which non-vitamin K antagonist oral anticoagulant (NOAC) therapy (apixaban, dabigatran, rivaroxaban, edoxaban) is most clinically and cost-effective. We aimed to elucidate methodological considerations and challenges involved in evaluating the comparative effectiveness and cost-effectiveness of within-class treatments for the  purpose of decision making by a reimbursement authority.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: A Briggs, A Howarth, S Davies, J Schneider, G Spentzouris, F Mughal, A Fuat, M Fay Source Type: research

Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol
DiscussionCurrent guidelines in the treatment of cerebral vein thrombosis dating back to 2011 from the American Heart Association/American Stroke Association endorse the utility of anticoagulation for the treatment of cerebral vein thrombosis; however, they did not support the use of direct oral anticoagulants. Updated guidelines from the European Stroke Organization, endorsed by the European Academy of Neurology in 2017, also refute utilization of direct oral anticoagulants due to a lack of evidence. There have been nearly 10  years of experience with direct oral anticoagulants in the treatment of venous thrombosis and ...
Source: Systematic Reviews - April 17, 2019 Category: International Medicine & Public Health Source Type: research

Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective
The objective of this study was to evaluate the cost-effectiveness of apixaban against other NOACs and warfarin from the considering costs and savings for public payers perspective in Kazakhstan
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: A Kostyuk, A Almadiyeva, T Nurgozhin Source Type: research

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with l...
Source: Health and Quality of Life Outcomes - June 21, 2017 Category: International Medicine & Public Health Authors: Shannon L. Reynolds, Sameer R. Ghate, Richard Sheer, Pranav K. Gandhi, Chad Moretz, Cheng Wang, Stephen Sander, Mary E. Costantino, Srinivas Annavarapu and George Andrews Source Type: research

Enrollment completed for RE-DUAL PCI ™ study of 2,700 atrial fibrillation patients
(WHITECOAT STRATEGIES, LLC) The Baim Institute announces that patient enrollment into the international Phase IIIb RE-DUAL PCI ™ study is complete. The study evaluates the safety and efficacy of dabigatran etexilate (marketed as Pradaxa ® ) in atrial fibrillation patients undergoing a percutaneous coronary intervention with stent placement. This is the first time that two dosages of a non-vitamin K antagonist oral anticoagulant already approved for stroke prevention in AF are evaluated in a dual versus triple antithrombotic regimen after PCI.
Source: EurekAlert! - Medicine and Health - November 14, 2016 Category: Global & Universal Source Type: news

PM198 Antithrombotic Treatment in Relation to Age and Stroke Risk in Patients With Newly Diagnosed Atrial Fibrillation (Gloria-AF Phase II)
Vitamin K antagonists (VKAs) or the non-VKA oral anticoagulants (NOACs) are recommended for prevention of stroke in patients with atrial fibrillation (AF) and additional stroke risk factors. Phase II of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) started after approval of dabigatran etexilate, the first NOAC available for stroke prevention in patients with AF.
Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: J. Halperin, M. Huisman, H.-C. Diener, S. Dubner, C. Ma, K. Rothman, J. Healey, K. Zint, C. Teutsch, G. Lip Tags: Poster Abstract Source Type: research

Trends in the Utilization of Warfarin and Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
Warfarin has been used for more than 60 years to decrease the risk of stroke and death in patients with atrial fibrillation (AF). In recent years, the FDA has approved four non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in AF: dabigatran, rivaroxaban, apixaban, and edoxaban.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Alalwan, S Voils, A Hartzema Source Type: research

The Uptake of Non-Vitamin K Oral Anticoagulants in Ireland: Balancing Cost-Effectiveness Analysis and Budget Impact
For many years vitamin K antagonists (usually warfarin) were the only oral anticoagulants available to reduce stroke risk in Atrial fibrillation (AF). The non-vitamin K oral anticoagulants (NOACs) were first licensed in Ireland for stroke prevention in non-valvular AF with the approval of dabigatran etexilate in 2011. Rivaroxaban followed later that year, apixaban in 2013 and edoxaban in 2015. The National Centre for Pharmacoeconomics (NCPE) reviewed all the NOACs for cost-effectiveness prior to reimbursement approval in Ireland.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Barry, S Clarke, N Geraghty Source Type: research

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants And Warfarin for Stroke Prevention In Atrial Fibrillation In Venezuela
Apixaban (5 mg BID), dabigatran (150mg), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF). Although warfarin remains the standard of care in Venezuela.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: Y Fernández Ávila, KC Garcia, S Garrido Lecca, BM Donato, A Juarez-Garcia Source Type: research

Cost-Effectiveness of Apixaban Versus Other Noacs And Warfarin, During Hospitalization In The Private Brazilian Health System
Atrial fibrillation (AF) is the most common arrhythmia in the world and it affects around 1% of the world´s population. There are approximately 1.5 million people, in Brazil, that have AF. AF is the fifth cause of hospitalization in the Public Health System. AF patients have an increased risk of developing an ischemic stroke than patients without AF. Current treatment for AF are vitamin K antagonist (AVKs), antiplatelet agents, acetylsalicylic acid (AAS) and the Oral Anticoagulants – NOACs (rivaroxaban, dabigatran and apixaban).
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: S Tanaka, MC Preto, G Bernardino, F Nogueira, CN Ferreira, BM Donato Source Type: research

Preliminary Study of Safety and Efficacy of Warfarin Versus Dabigatran in Atrial Fibrillation Patients in a Tertiary Hospital in Malaysia
This study aims to compare the pattern of anticoagulants used and to assess their safety and efficacy by evaluating bleeding and stroke occurrences in both groups.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Mohd Hajiri, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research

Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives
Conclusions Dabigatran use improves patient survival and quality of life compared with warfarin. This represents the best therapeutic option in terms of cost and effectiveness in the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Source: Value in Health Regional Issues - June 10, 2015 Category: Global & Universal Source Type: research

Economic Evaluation Of Dabigatran Etexilate Versus Warfarin, Rivaroxaban And Apixaban In Stroke Prevention In Atrial Fibrilation
To determine the economic value of dabigatran for stroke prevention in atrial fibrillation (SPAF) compared to other reimbursed oral anticoagulants warfarin, rivaroxaban and apixaban from a perspective of Mexican public institutions.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: J.L. Huicochea-Bartelt, J. Gay-Molina, L.A. Ortiz-Blas, S. Herran Source Type: research

Cost-Efectiveness Of Dabigatran In Non Valvular Atrial Fibrillation In Colombia
Atrial fibrillation (AF) is the most common cardiac rhythm disorder; it increases stroke risk 5 to 6 times. Prevalence in Colombia has been estimated in 3.6% in population age 60 or over (some 180 000 potential patients). The aim of this study was to estimate cost-effectiveness of dabigatran 110 mg and 150 mg BID as a therapy for non valvular AF in Colombian population.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: J.J. Triana, C. Castañeda-Cardona, L. Parada, D. Rosselli Source Type: research

Medicare beneficiary out-of-pocket spending for stroke prevention in non-valvular Atrial Fibrillation: a budget analysis
Healthcare costs today are increasingly being shifted from payers to patients, yet few providers factor patient costs into treatment decisions. Recent advancements in stroke prevention in atrial fibrillation (AF) have resulted in new treatment options where previously there were few. While the clinical benefit and cost effectiveness of these treatments are supported by a growing body of evidence, the cost impact to patients has not been explored. This analysis sought to quantify patient out-of-pocket costs for three stroke prevention strategies: warfarin, dabigatran and left atrial appendage closure (LAAC) with the Watchman Device.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: S. Armstrong, S.L. Amorosi, G. Erickson, P. Patel, K. Stein Source Type: research

Pages: 1  2